 | |  | |  | |  | |  | |  | |  | |  |
| IJCEM Copyright © 2008-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711 |
Int J Clin Exp Med 2012;5(3):229-237
Original Article
Serum insulin-like growth factor binding protein 6 (IGFBP6) is increased in patients
with type 1 diabetes and its complications
Shangsu Lu*, Sharad Purohit*, Ashok Sharma*, Wenbo Zhi*, Mingfang He, Yiqian Wang, Chao-Jun Li, Jin-Xiong She
Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing 210046,
China; Jiangsu Institute of Translational Medicine and School of Pharmaceutical Sciences, Nanjing University of Technology, Nanjing,
Jiangsu, China; Center for Biotechnology and Genomic Medicine and Department of Pathology, Medical College of Georgia, Georgia
Health Sciences University, Augusta, Georgia, United States of America; Zhangjiagang entry-exit inspection and Quarantine Bureau,
Zhangjiagang, 215600, China; *These authors contributed equally to this study.
Received April 3, 2012; accepted May 15, 2012; Epub June 10, 2012; Published June 30, 2012
Abstract: Insulin-like growth factor binding proteins (IGFBPs) are associated with insulin resistance and accelerated micro- and
macro-vascular complications of diabetes. We investigated the relationship between serum levels of IGFBP6 in type-1 diabetes (T1D)
patients and diabetic complications. In this study, IGFBP6 was measured in the sera from 697 T1D patients and 681 healthy controls
using a Luminex assay. Mean serum levels of IGFBP6 were higher in T1D patients than controls matched for sex and age (119.7 vs
130.6 ng/ml, p < 10-4). Subject age, sex and duration of disease have a significant impact on serum IGFBP6 levels in both T1D patients
and healthy controls. Patients with complications have significantly higher mean serum IGFBP6 than patients without any complication
(p = 3.5x10-6). More importantly, conditional logistic regression analysis suggested that T1D patients are more likely to have very high
levels of serum IGFBP6 (in the 4th quartile) (OR = 1.7) than healthy controls. Furthermore, T1D patients with various complications are
more likely to have very high levels of serum IGFBP6 (in the 4th quartile) than patients without any complication (OR = 1.7 - 22.9). These
results indicate the clinical importance of measuring IGFBP6 to the better management of T1D patients. (IJCEM1204003)
Keywords: Insulin-like growth factor binding proteins (IGFBPs), insulin resistance, diabetes, complications
Address all correspondence to:
Dr. Jin-Xiong She, Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Georgia Health Sciences University,
1120 15th Street, Augusta, GA 30912 Tel: 706-721-3410; Fax: 706-721-3688; E-mail: jshe@georgiahealth.edu. Dr. Chao-Jun Li,
Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing 210046,
China Tel: 86-13813896000; E-mail: licj@nju.edu.cn
Original Article
Serum insulin-like growth factor binding protein 6 (IGFBP6) is increased in patients
with type 1 diabetes and its complications
Shangsu Lu*, Sharad Purohit*, Ashok Sharma*, Wenbo Zhi*, Mingfang He, Yiqian Wang, Chao-Jun Li, Jin-Xiong She
Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing 210046,
China; Jiangsu Institute of Translational Medicine and School of Pharmaceutical Sciences, Nanjing University of Technology, Nanjing,
Jiangsu, China; Center for Biotechnology and Genomic Medicine and Department of Pathology, Medical College of Georgia, Georgia
Health Sciences University, Augusta, Georgia, United States of America; Zhangjiagang entry-exit inspection and Quarantine Bureau,
Zhangjiagang, 215600, China; *These authors contributed equally to this study.
Received April 3, 2012; accepted May 15, 2012; Epub June 10, 2012; Published June 30, 2012
Abstract: Insulin-like growth factor binding proteins (IGFBPs) are associated with insulin resistance and accelerated micro- and
macro-vascular complications of diabetes. We investigated the relationship between serum levels of IGFBP6 in type-1 diabetes (T1D)
patients and diabetic complications. In this study, IGFBP6 was measured in the sera from 697 T1D patients and 681 healthy controls
using a Luminex assay. Mean serum levels of IGFBP6 were higher in T1D patients than controls matched for sex and age (119.7 vs
130.6 ng/ml, p < 10-4). Subject age, sex and duration of disease have a significant impact on serum IGFBP6 levels in both T1D patients
and healthy controls. Patients with complications have significantly higher mean serum IGFBP6 than patients without any complication
(p = 3.5x10-6). More importantly, conditional logistic regression analysis suggested that T1D patients are more likely to have very high
levels of serum IGFBP6 (in the 4th quartile) (OR = 1.7) than healthy controls. Furthermore, T1D patients with various complications are
more likely to have very high levels of serum IGFBP6 (in the 4th quartile) than patients without any complication (OR = 1.7 - 22.9). These
results indicate the clinical importance of measuring IGFBP6 to the better management of T1D patients. (IJCEM1204003)
Keywords: Insulin-like growth factor binding proteins (IGFBPs), insulin resistance, diabetes, complications
Address all correspondence to:
Dr. Jin-Xiong She, Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Georgia Health Sciences University,
1120 15th Street, Augusta, GA 30912 Tel: 706-721-3410; Fax: 706-721-3688; E-mail: jshe@georgiahealth.edu. Dr. Chao-Jun Li,
Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing 210046,
China Tel: 86-13813896000; E-mail: licj@nju.edu.cn
